Lilly to acquire three vaccine developers for nearly $4-billion
Eli Lilly has announced plans to acquire three vaccine developers for nearly $4 billion, marking a significant expansion into infectious disease prevention. The acquisitions include Curevo, LimmaTech Biologics, and Vaccine Co., each focusing on different vaccine developments. This move follows Lilly's recent success in the obesity drug market, allowing the company to diversify its therapeutic portfolio.
- ▪Eli Lilly will acquire Curevo for up to $1.5 billion, which is developing a shingles vaccine.
- ▪LimmaTech Biologics will be acquired for up to $780 million, focusing on vaccines against bacterial pathogens.
- ▪The Vaccine Co. is developing a vaccine for Epstein-Barr virus, with Lilly agreeing to pay up to $1.55 billion.
5 outlets in our directory ran this story, first to last over 6 hours. Coverage spans 2 points on the political spectrum — 1 lean left, 2 centre.
- ▪ Lilly to buy three vaccine developers for nearly $4 billion in infectious disease push - Reuters — Google News
- ▪ Eli Lilly to Buy 3 Vaccine Developers — NYT — Business
- ▪ Eli Lilly acquires three vaccine developers for $3.8 billion — Yahoo Finance
- ▪ STAT+: Eli Lilly to buy three small vaccine developers — STAT News
The Globe and Mail publishes from Canada and files mainly under world. We currently carry 1,935 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | The Globe and Mail |
| Canonical URL | https://www.theglobeandmail.com/business/article-eli-lilly-buy-vaccine-developers-curevo-limmatech/ |
| Publication time | Tue, 26 May 2026 11:16:20 +0000 |
| Retrieval time | 2026-05-26T11:22:48.612Z |
| Last seen | 2026-05-26T11:22:48.612Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | PMrJ3syZyOpk · 5 stories |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
ShareSave for laterPlease log in to bookmark this story.Log InCreate Free AccountEli Lilly LLY-N said on Tuesday it will buy three vaccine developers in deals worth up to nearly US$4-billion in combined value, signalling a push by the drugmaker into infectious disease prevention.The drugmaker riding a wave of cash from the booming demand for its obesity drugs has been on an acquisition spree as it expands beyond weight loss to other therapeutic areas.The company has agreed to acquire Curevo, LimmaTech Biologics and Vaccine Co.Lilly shares were up 1.6 per cent in premarket trading.Curevo shareholders could receive up to US$1.5-billion in cash, inclusive of an upfront payment, and a subsequent payment on achieving a specified milestone.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at The Globe and Mail.
Discussion
0 commentsMore from The Globe and Mail
